Literature DB >> 8839037

Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.

C Iribarne1, F Berthou, S Baird, Y Dréano, D Picart, J P Bail, P Beaune, J F Ménez.   

Abstract

Methadone has become one of the most widely used drugs for opiate dependency treatment. This drug is extensively metabolized by the cytochrome P450 hepatic enzyme family in man, yielding an N-demethylated metabolite that cyclizes spontaneously into 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine. The specific forms of cytochrome P450 involved in this oxidative N-demethylation were examined in a panel of 20 human liver microsomal preparations previously characterized with respect to their P450 enzyme contents. Methadone was demethylated with an apparent Km of 545 +/- 258 microM (n = 3). The metabolic rates were 745 +/- 574 pmol/(min.mg of protein). This metabolic pathway was strongly correlated with estradiol 2-hydroxylation, testosterone 6 beta-hydroxylation, nifedipine oxidation, erythromycin N-demethylation, and toremifene N-demethylation, all of these monooxygenase activities being supported by P450 3A4. Furthermore, the total P450 3A content of liver microsomal samples, determined by immuno-quantification using a monoclonal anti-human P450 3A4 antibody, was correlated with methadone demethylation (r = 0.72; p < 0.003). Methadone metabolism was 60-72% inhibited either by three mechanism-based inhibitors of P450 3A4 (gestodene, TAO, and erythralosamine) or by four reversible inhibitors of P450 3A (ketoconazole, dihydroergotamine, quercetin, and diazepam with an apparent Ki of 50 microM) and by two nonspecific inhibitors (metyrapone and SKF-525A). Conversely, quinidine (inhibitor of P450 2D6), 7,8-benzoflavone (inhibitor of P450 1A), or sulfaphenazole (inhibitor of P450 2C) did not significantly inhibit, and may even have activated, methadone metabolism. Four heterologously expressed P450 proteins were able to catalyze the N-demethylation of methadone, namely, P450 2C8, P450 2C18, P450 2D6, and P450 3A4. However, referring to their relative liver content, it can be asserted that P450 3A4 is the major enzyme involved in the N-demethylation of methadone on average. Accordingly, caution should be advised in the clinical use of methadone when other drugs are also administered that induce or inhibit P450 3A4, such as rifampicin or diazepam, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839037     DOI: 10.1021/tx950116m

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  51 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

3.  Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility.

Authors:  Robert K Vinson
Journal:  Clin Drug Investig       Date:  2012-07-01       Impact factor: 2.859

4.  Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.

Authors:  Yan Chang; Wenfang B Fang; Shen-Nan Lin; David E Moody
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-09-02       Impact factor: 4.080

5.  Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).

Authors:  Evan D Kharasch; Pamela Sheffels Bedynek; Christine Hoffer; Alysa Walker; Dale Whittington
Journal:  Anesthesiology       Date:  2012-02       Impact factor: 7.892

Review 6.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

7.  Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

Authors:  Evan D Kharasch; Alysa Walker; Dale Whittington; Christine Hoffer; Pamela Sheffels Bedynek
Journal:  Drug Alcohol Depend       Date:  2009-02-18       Impact factor: 4.492

8.  Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.

Authors:  Evan D Kharasch; Karen J Regina; Jane Blood; Christina Friedel
Journal:  Anesthesiology       Date:  2015-11       Impact factor: 7.892

9.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.

Authors:  E D Kharasch; P S Bedynek; S Park; D Whittington; A Walker; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

10.  Relationship between methadone and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) in urine samples from Norwegian prisons.

Authors:  Jean-Paul Bernard; Mimi Stokke Opdal; Ritva Karinen; Jørg Mørland; Hassan Z Khiabani
Journal:  Eur J Clin Pharmacol       Date:  2007-06-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.